drug
Slynd
Marketedupdated 3mo agoby Exeltis USA Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4all catalysts(0)
nothing on the calendar yet
Trials studying Slynd
- phase1A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- phase4LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
- phase3Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
- phase1A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®)
- phase1A Study of Milvexian in Healthy Adult Females
- phase1Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
- phase1A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- phase1Drospirenone (3 mg) + Ethinyl Estradiol (0.02 mg) Tablets Relative to Yaz®
Patent cliff
source: FDA Orange Bookfirst barrier falls
Feb 8, 2030
~3.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (32)
- Jun 28, 2031method-of-use (U-2553)US 101791404.9y
- Jun 28, 2031method-of-use (U-2553)US 101791404.9y
- Jun 28, 2031method-of-use (U-2553)US 106032814.9y
- Jun 28, 2031method-of-use (U-2553)US 106032814.9y
- Jun 28, 2031formulationUS 108498574.9y
- Jun 28, 2031formulationUS 108498574.9y
- Jun 28, 2031formulationUS 109873644.9y
- Jun 28, 2031formulationUS 109873644.9y
- Jun 28, 2031formulationUS 111232994.9y
- Jun 28, 2031formulationUS 111232994.9y
- Jun 28, 2031formulationUS 112916324.9y
- Jun 28, 2031formulationUS 112916324.9y
- Jun 28, 2031formulationUS 112916334.9y
- Jun 28, 2031formulationUS 112916334.9y
- Jun 28, 2031formulationUS 113511224.9y
- Jun 28, 2031formulationUS 113511224.9y
- Jun 28, 2031method-of-use (U-2553)US 114132494.9y
- Jun 28, 2031method-of-use (U-2553)US 114132494.9y
- Jun 28, 2031formulationUS 114395984.9y
- Jun 28, 2031formulationUS 114784874.9y
- Jun 28, 2031formulationUS 114784874.9y
- Jun 28, 2031formulationUS 115043344.9y
- Jun 28, 2031formulationUS 115043344.9y
- Jun 28, 2031method-of-use (U-2553)US 119512134.9y
- Jun 28, 2031method-of-use (U-2553)US 119512134.9y
- Jun 28, 2031method-of-use (U-2553)US 120902314.9y
- Jun 28, 2031method-of-use (U-2553)US 120902314.9y
- Jun 28, 2031formulationUS 122801514.9y
- Jun 28, 2031method-of-use (U-2553)US 96038604.9y
- Jun 28, 2031method-of-use (U-2553)US 96038604.9y
- Jul 17, 2030formulationUS 116177513.9y
- Feb 8, 2030formulationUS 86175973.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that